BGIM
HALO icon

Boussard & Gavaudan Investment Management’s Halozyme HALO Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,964
Closed -$859K – 86
2023
Q3 		$859K Buy
+21,964
New +$900K 0.1% 66
2023
Q2 		– Sell
-12,956
Closed -$480K – 129
2023
Q1 		$480K Buy
+12,956
New +$608K 0.05% 86

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boussard & Gavaudan Investment Management's HALO Position: Q4 2023 in Review

Boussard & Gavaudan Investment Management sold out of Halozyme (HALO) in Q4 2023, closing a stake of 21,964 shares — an estimated $859K sold.

Boussard & Gavaudan Investment Management first reported a position in HALO in Q1 2023 and held it in 2 quarters. The position peaked at $859K in Q3 2023. 410 funds tracked by Wall St. Rank hold HALO as of Q4 2023.

  • Boussard & Gavaudan Investment Management reported no remaining Halozyme position as of Q4 2023 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 21,964 Halozyme shares in Q4 2023, an estimated $859K.
  • Boussard & Gavaudan Investment Management first reported a position in Halozyme in Q1 2023 and held it in 2 quarters.
  • Boussard & Gavaudan Investment Management's Halozyme position peaked at $859K in Q3 2023.
  • 410 funds tracked by Wall St. Rank held Halozyme as of Q4 2023.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q4 2023, filed 13 Feb 2024.